Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range

Blood - Tập 96 Số 3 - Trang 846-851 - 2000
Andreas Greinacher1, Petra Eichler1, Norbert Lübenow1, Harald Kwasny1, Matthias Luz1
1From the Institute for Immunology and Transfusion Medicine, Ernst–Moritz–Arndt University Greifswald; the Biometrics Department, Aventis–Behring, Marburg; and the Clinical Operations Department, Aventis Pharma, Frankfurt, Germany.

Tóm tắt

Abstract This meta-analysis focuses on 2 prospective studies in patients with heparin-induced thrombocytopenia (HIT) and thromboembolic complication (TEC) who were treated with lepirudin (n = 113). Data were compared with those of a historical control group (n = 91). The primary endpoint (combined incidence of death, new TEC, and limb amputation) occurred in 25 lepirudin-treated patients (22.1%; 95% CI, 14.5%-29.8%): 11 died (9.7%; 95% CI, 4.9%-16.8%), 7 underwent limb amputation (6.2%; 95% CI, 2.5%-12.3%), and 12 experienced new TEC (10.6%; 95% CI, 5.8%-18.3%). The risk was highest in the period between diagnosis of HIT and the start of lepirudin therapy (combined event rate per patient day 6.1%). It markedly decreased to 1.3% during lepirudin treatment and to 0.7% in the posttreatment period. From the start of lepirudin therapy to the end of follow-up, lepirudin-treated patients had consistently lower incidences of the combined endpoint than the historical control group (P = .004, log-rank test), primarily because of a reduced risk for new TEC (P = .005). Thrombin–antithrombin levels in the pretreatment period (median, 43.9 μg/L) decreased after the initiation of lepirudin (at 24 hours ± 6 hours; median, 9.18 μg/L.) During treatment with lepirudin, aPTT ratios of 1.5 to 2.5 produced optimal clinical efficacy with a moderate risk for bleeding, aPTT ratios lower than 1.5 were subtherapeutic, and aPTT levels greater than 2.5 were associated with high bleeding risk. Bleeding events requiring transfusion were significantly more frequent in patients taking lepirudin than in historical control patients (P = .02). In conclusion, this meta-analysis provides further evidence that lepirudin is an effective and acceptably safe treatment for patients with HIT.

Từ khóa


Tài liệu tham khảo

Warkentin, 1998, Heparin-induced thrombocytopenia: towards consensus., Thromb Haemost., 79, 1, 10.1055/s-0037-1614206

Warkentin, 1995, Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin., N Engl J Med., 332, 1330, 10.1056/NEJM199505183322003

Amiral, 1995, Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases., Thromb Haemost., 73, 21, 10.1055/s-0038-1651670

Amiral, 1996, Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia., Br J Haematol., 92, 954, 10.1046/j.1365-2141.1996.407945.x

Cines, 1987, Immune endothelial-cell injury in heparin-associated thrombocytopenia., N Engl J Med., 316, 58, 10.1056/NEJM198703053161004

Visentin, 1994, Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells., J Clin Invest., 93, 81, 10.1172/JCI116987

Greinacher, 1994, Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen., Thromb Haemost., 71, 247

Chong, 1989, Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets., Br J Haematol., 73, 235, 10.1111/j.1365-2141.1989.tb00258.x

Kelton, 1988, Heparin-induced thrombocytopenia: laboratory studies., Blood., 72, 925, 10.1182/blood.V72.3.925.bloodjournal723925

Chong, 1994, Plasma P-selectin is increased in thrombotic consumptive platelet disorders., Blood., 83, 1535, 10.1182/blood.V83.6.1535.1535

Warkentin, 1994, Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia., Blood., 84, 3691, 10.1182/blood.V84.11.3691.bloodjournal84113691

Greinacher, 1999, Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia., Circulation., 100, 587, 10.1161/01.CIR.100.6.587

Warkentin, 1998, Limitations of conventional treatment options for heparin-induced thrombocytopenia., Semin Hematol., 35(suppl 4), 17

Parent, 1993, Treatment of severe venous thromboembolism with intravenous hirudin (HBW 023): an open pilot study., Thromb Haemost., 70, 386, 10.1055/s-0038-1649590

Stringer, 1992, Hirudins: antithrombin anticoagulants., Ann Pharmacother., 26, 1535, 10.1177/106002809202601211

Weitz, 1990, Clot bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors., J Clin Invest., 86, 385, 10.1172/JCI114723

Weitz, 1998, Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors., Circulation., 97, 544, 10.1161/01.CIR.97.6.544

Greinacher, 1999, Recombinant hirudin (lepirudin) provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia type II: a prospective study., Circulation., 99, 73, 10.1161/01.CIR.99.1.73

Greinacher, 1991, A rapid and sensitive test for diagnosing heparin associated thrombocytopenia., Thromb Haemost., 66, 734, 10.1055/s-0038-1646493

Eichler, 1999, First workshop for detection of heparin-induced antibodies: validation of the heparin-induced-platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA., Thromb Haemost., 81, 625, 10.1055/s-0037-1614536

Schiele, 1997, Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial., Thromb Haemost., 77, 834, 10.1055/s-0038-1656063

Kalbfleisch, 1980, The Statistical Analysis of Failure Time Data.

Warkentin, 1996, A 14-year study of heparin-induced thrombocytopenia., Am J Med., 101, 502, 10.1016/S0002-9343(96)00258-6

Nand, 1997, Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution., Am J Hematol., 56, 12, 10.1002/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5

Warkentin, 1997, The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia., Ann Intern Med., 127, 804, 10.7326/0003-4819-127-9-199711010-00005

Nurmohamed, 1994, Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment., Thromb Haemost., 72, 685, 10.1055/s-0038-1648943

Pötzsch, 1997, The whole blood ecarin clotting time assay allows rapid and accurate monitoring of the anticoagulant response of r-hirudin during cardio-pulmonary bypass., Thromb Haemost., 77, 920, 10.1055/s-0038-1656078

Thông tin
Thông tin xuất bản

Blood

Tập 96 Số 3

846-851

Thông tin tác giả